Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Food Funct ; 8(10): 3510-3522, 2017 Oct 18.
Artículo en Inglés | MEDLINE | ID: mdl-28875188

RESUMEN

Epidemiological and clinical studies suggest that grapes and grape-derived products may reduce the risk for chronic disease. Grape seed extract specifically has been gaining interest due to its reported ability to prevent weight gain, moderate hyperglycemia, and reduce inflammation. The purpose of this study was to examine the long-term effects of two doses of grape seed extract (10 and 100 mg kg-1 body wt per d in mice) on markers of metabolic syndrome in the context of a moderately high-fat diet. After 12 weeks, the lower dose of grape seed extract was more effective at inhibiting fat gain and improving glucose tolerance and insulin sensitivity. Neither the high fat diet nor grape seed extract altered skeletal muscle substrate metabolism. Most interestingly, when examining the profile of metabolically active microbiota in the mucosa of the small intestine, cecum, and colonic tissue, grape seed extract seemed to have the most dramatic effect on small intestinal tissue, where the population of Firmicutes was lower compared to control groups. This effect was not observed in the cecal or colonic tissues, suggesting that the main alterations to gut microbiota due to flavan-3-ol supplementation occur in the small intestine, which has not been reported previously. These findings suggest that grape seed extract can prevent early changes in glucose tolerance and alter small intestinal gut microbiota, prior to the onset of skeletal muscle metabolic derangements, when grape seed extract is consumed at a low dose in the context of a moderately high fat diet.


Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Microbioma Gastrointestinal/efectos de los fármacos , Extracto de Semillas de Uva/administración & dosificación , Intestino Delgado/microbiología , Obesidad/tratamiento farmacológico , Animales , Bacterias/clasificación , Bacterias/genética , Bacterias/aislamiento & purificación , Glucemia/metabolismo , Diabetes Mellitus/metabolismo , Diabetes Mellitus/microbiología , Dieta Alta en Grasa/efectos adversos , Humanos , Insulina/metabolismo , Intestino Delgado/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Obesidad/metabolismo , Obesidad/microbiología , Vitis/química
2.
J Agric Food Chem ; 62(10): 2216-27, 2014 Mar 12.
Artículo en Inglés | MEDLINE | ID: mdl-24559282

RESUMEN

There is interest in the potential of cocoa flavanols, including monomers and procyanidins, to prevent obesity and type-2 diabetes. Fermentation and processing of cocoa beans influence the qualitative and quantitative profiles of individual cocoa constituents. Little is known regarding how different cocoa flavanols contribute to inhibition of obesity and type-2 diabetes. The objective of this study was to compare the impacts of long-term dietary exposure to cocoa flavanol monomers, oligomers, and polymers on the effects of high-fat feeding. Mice were fed a high-fat diet supplemented with either a cocoa flavanol extract or a flavanol fraction enriched with monomeric, oligomeric, or polymeric procyanidins for 12 weeks. The oligomer-rich fraction proved to be most effective in preventing weight gain, fat mass, impaired glucose tolerance, and insulin resistance in this model. This is the first long-term feeding study to examine the relative activities of cocoa constituents on diet-induced obesity and insulin resistance.


Asunto(s)
Biflavonoides/química , Biflavonoides/farmacología , Cacao/química , Catequina/química , Catequina/farmacología , Flavonoles/química , Flavonoles/farmacología , Resistencia a la Insulina , Obesidad/prevención & control , Proantocianidinas/química , Proantocianidinas/farmacología , Animales , Composición Corporal/efectos de los fármacos , Cromatografía Líquida de Alta Presión/métodos , Dieta Alta en Grasa , Ingestión de Alimentos/efectos de los fármacos , Flavonoles/análisis , Intolerancia a la Glucosa/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos C57BL , Obesidad/etiología , Relación Estructura-Actividad , Espectrometría de Masas en Tándem/métodos , Aumento de Peso/efectos de los fármacos
3.
Nutr Res ; 32(10): 787-94, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23146776

RESUMEN

Animal studies have demonstrated the potential of grape seed extract (GSE) to prevent metabolic syndrome, obesity, and type 2 diabetes. Recently, metabolic endotoxemia induced by bacterial endotoxins produced in the colon has emerged as a possible factor in the etiology of metabolic syndrome. Improving colonic barrier function may control endotoxemia by reducing endotoxin uptake. However, the impact of GSE on colonic barrier integrity and endotoxin uptake has not been evaluated. We performed a secondary analysis of samples collected from a chronic GSE feeding study with pharmacokinetic end points to examine potential modulation of biomarkers of colonic integrity and endotoxin uptake. We hypothesized that a secondary analysis would indicate that chronic GSE administration increases colonic expression of intestinal tight junction proteins and reduces circulating endotoxin levels, even in the absence of an obesity-promoting stimulus. Wistar Furth rats were administered drinking water containing 0.1% GSE for 21 days. Grape seed extract significantly increased the expression of gut junction protein occludin in the proximal colon and reduced fecal levels of the neutrophil protein calprotectin, compared with control. Grape seed extract did not significantly reduce serum or fecal endotoxin levels compared with control, although the variability in serum levels was widely increased by GSE. These data suggest that the improvement of gut barrier integrity and potential modulation of endotoxemia warrant investigation as a possible mechanism by which GSE prevents metabolic syndrome and associated diseases. Further investigation of this mechanism in high-fat feeding metabolic syndrome and obesity models is therefore justified.


Asunto(s)
Colon/efectos de los fármacos , Endotoxinas/metabolismo , Extracto de Semillas de Uva/farmacología , Mucosa Intestinal/efectos de los fármacos , Complejo de Antígeno L1 de Leucocito/metabolismo , Ocludina/metabolismo , Vitis/química , Animales , Colon/metabolismo , Dieta , Endotoxemia/complicaciones , Endotoxinas/sangre , Heces/química , Extracto de Semillas de Uva/administración & dosificación , Mucosa Intestinal/metabolismo , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/etiología , Síndrome Metabólico/prevención & control , Fitoterapia , Ratas , Ratas Wistar , Valores de Referencia , Uniones Estrechas/efectos de los fármacos , Uniones Estrechas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA